此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

破译 HCV 相关肝纤维化范围内微生物易位的机制

破译 HCV 相关肝纤维化范围内微生物易位机制的多学科方法

Background:

- Hepatitis C infection (HCV) is a leading cause of liver disease. Normal bacteria from the intestines may spread to the liver and blood during liver disease. This is called bacterial translocation (BT). Researchers think BT may cause liver disease to worsen.

Objectives:

- To study the mechanisms involved in BT in early and advanced liver disease. To find out whether BT causes liver disease to worsen.

Eligibility:

- People over age 18 with HCV and clinically stable liver disease.

Design:

  • Participants will be screened with medical history and physical exam. They will have blood tests and imaging studies.
  • Participants will have 2 outpatient visits and a 3-day stay at the clinic.
  • At visit 1, participants will have urine and blood tests. They will have a magnetic resonance imaging (MRI) scan. A solution will be injected into a vein. The MRI scanner is a metal cylinder surrounded by a magnetic field. The participant will lie on a table that slides in and out of the cylinder.
  • At visit 2, a substance will be injected into a vein and swallowed. Participants will then have blood drawn 5 times over 90 minutes.
  • During the inpatient stay, serial blood tests will be drawn.
  • Participants will give 2 stool samples and have another MRI.
  • A needle will be inserted through the chest wall into a vein inside the liver, guided by ultrasound. The blood pressure inside this vein will be measured and blood will be drawn from it. About 1 inch of liver tissue will be removed.
  • A study investigator will call participants to discuss all test results.

研究概览

地位

完全的

条件

干预/治疗

详细说明

Hepatitis C (HCV) is a leading cause of cirrhosis worldwide. Most complications associated with cirrhosis are driven by an altered portal circulation and the development of portal hypertension. Bacterial translocation (BT) from the gut to the systemic circulation is considered a pivotal mechanism contributing to the development of life-threatening complications in end stage cirrhosis. Recent evidence suggests that the liver and systemic circulation may be exposed to gut derived microbial products at earlier stages of liver disease. This early exposure may trigger hepatic inflammation, modify immune host response and accelerate hepatic fibrogenesis; which, in turn, impairs portal inflow, alters the portal circulation, and leads to development of portal hypertension. The mechanisms resulting in systemic exposure to gut derived microbial products, and the subsequent host response to BT has not been studied in patients with early liver disease nor fully compensated cirrhosis.

We therefore intend to enroll 30 chronic HCV patients with either cirrhosis (20) or minimal liver fibrosis (10). Study participants will undergo extensive evaluation with portal vein sampling and pressure measurements, dual cholate clearances, liver biopsy, serologic, immunologic, fecal microbiome and imaging studies. This will be followed by an optional second percutaneous liver biopsy and portal vein sampling 9-15 months after HCV treatment. The treatment protocol is a separate independent protocol, 15-DK- 0143 utilizing Sofosbuvir and GS-5816. The goals of our study are to characterize the extent of BT in early stages of cirrhotic and non-cirrhotic liver disease, explore the mechanisms contributing to its occurrence and identify potential serological, immunological and hemodynamic biomarkers associated with chronic infection. This, in turn, can aid in establishing a possible link between BT, subsequent host responses and severity of liver disease.

研究类型

观察性的

注册 (实际的)

30

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Maryland
      • Bethesda、Maryland、美国、20892
        • National Institutes of Health Clinical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Primary clinical patients with chronic HCV infection divided into 2 groups according to liver fibrosis stage.

描述

  • INCLUSION CRITERIA:

    1. All age greater than 18 male or female
    2. Capacity to provide written informed consent
    3. Evidence of HCV RNA in 2 serum samples at least 6 months apart.
    4. All HCV genotypes
    5. Liver biopsy in the last 2 years prior to enrollment showing Ishak fibrosis score of either 0-1 or 5-6. An alternative to liver biopsy will be a Fibroscan study performed in the 6 months prior to study enrollment showing a score of either kPa <7 or above 13.
    6. Child-Pugh score less than or equal to 6
    7. Prior to each liver biopsy and portal vein cannulation procedure, blood will be drawn for CBC, PT/INR & acute care panel.

EXCLUSION CRITERIA:

  1. Pregnant women or females at child bearing age not taking measures to prevent pregnancy during the period of study

  2. Patients currently on treatment for hepatitis C

  3. Clinical, serologic or histopathologic evidence supporting other etiologies of chronic liver disease besides HCV

  4. Current or past clinical evidence of decompensated liver disease (e.g. ascites, bleeding esophageal varices, spontaneous bacterial peritonitis, encephalopathy etc.)

  5. Cross sectional liver imaging study from the past 6 months showing a focal lesion suspicious of hepatocellular carcinoma and/or alpha-fetoprotein level greater than 200 ng/mL.

  6. Patients with active bacterial, viral or fungal, systemic or localized infection.

  7. Antibiotic treatment 30 days prior to study enrollment

  8. History of chronic inflammatory diseases of the bowel (Crohn s disease, Ulcerative colitis and celiac disease)

  9. History of congestive heart failure of moderate to severe degree.

  10. History of non-cirrhotic portal hypertension or portal vein thrombosis

  11. Patients with severe allergic reactions to iodine contrast, which cannot be controlled by premedication with antihistamines and steroids.

  12. EXCLUSION CRITERIA FOR MRI:

    12.1 Subjects with contraindication to MRI scanning. These contraindications include but are not limited to the following devices or conditions:

    <TAB>a. Implanted cardiac pacemaker or defibrillator

    <TAB>b. Cochlear Implants

    <TAB>c. Ocular foreign body (e.g. metal shavings)

    <TAB>d. Embedded shrapnel fragments

    <TAB>e. Central nervous system aneurysm clips

    <TAB>f. Implanted neural stimulator

    <TAB>g. Medical infusion pumps

    <TAB>h. Any implanted device that is incompatible with MRI.

    12.2 Unsatisfactory performance status as judged by the referring physician such that the subject could not tolerate an MRI scan. Examples of medical conditions that would not be accepted would include unstable angina and dyspnea at rest.

    12.3 Subjects requiring sedation for MRI studies.

    12.4 Subjects with a condition precluding entry into the scanner (e.g. morbid obesity, claustrophobia, etc.).

    12.5 Pregnant or lactating women.

    12.6 Subjects with severe back-pain or motion disorders who will be unable to tolerate supine positioning within the MRI scanner and hold still for the duration of the examination.

    12.7 For Gadolinium based and SPIO MRI Use:

    <TAB>a. History of severe allergic reaction to these contrast agents despite the use of premeditation with an anti-histaminic and cortisone.

    <TAB>b. eGFR < 60 ml/min/1.73m^2

  13. Absolute neutrophil count below 1000/mm^3, Hemoglobin level below 10.0 g/dl or platelet count lower than 70,000/mm^3.

  14. INR greater than or equal to 1.5, PTT greater than or equal to 1.3 times control and/or any known history of disease associated with increased bleeding diathesis.

  15. Serum creatinine greater than or equal to 2.0 mg/dl unless the measured creatinine clearance is greater than 60 mL/min

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_ONLY
  • 时间观点:CROSS_SECTIONAL

队列和干预

团体/队列
干预/治疗
Group A

Patients with fibrosis levels spanning from bridging fibrosis to cirrhosis (Ishak fibrosis score 5-6)

test for defining disease severity

Group B

Patients with minimal fibrosis (Ishak score 0-1).

test for defining disease severity

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Microbial product detection rate
大体时间:Before anti viral therapy and 9-15 months after treatment

Assess the extent of BT, explore possible mechanisms accounting for its occurrence and evaluate its effects on the immune system in different stages of liver fibrosis

Before anti viral therapy and 9-15 months after treatment

次要结果测量

结果测量
措施说明
大体时间
Dual-cholate liver function tests
大体时间:Baseline, and 9-15 months after treatment

Comparison of dual-cholate liver function tests and its association with microbial product levels in portal and systemic blood, between group A and group B patients.

Baseline, and 9-15 months after treatment
SPIO-MRI Kupffer cell uptake
大体时间:Baseline, and 9-15 months after treatment

Comparison of SPIO-MRI Kupffer cell uptake values and its association with microbial product levels in portal and systemic blood between group A and group B patients.

Baseline, and 9-15 months after treatment
Immune activation markers
大体时间:Baseline, and 9-15 months after treatment

Comparison of immune activation markers to bacterial products in liver tissue between group A and group B patients before and after HCV treatment.

Baseline, and 9-15 months after treatment
Pro and anti-inflammatory gene transcription
大体时间:Baseline, and 9-15 months after treatment

Comparison of pro and anti-inflammatory gene transcription analysis in between group A and group B patients

Baseline, and 9-15 months after treatment
Fecal microbiome
大体时间:Baseline, and 9-15 months after treatment

Comparison of fecal microbiome analysis between group A and group B patients

Baseline, and 9-15 months after treatment
Species homology
大体时间:Baseline, and 9-15 months after treatment

Evaluation of species homology between microbial DNA identified in portal and systemic blood and fecal samples by deep sequencing.

Baseline, and 9-15 months after treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Theo Heller, M.D.、National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2015年5月29日

初级完成 (实际的)

2017年2月24日

研究完成 (实际的)

2017年4月25日

研究注册日期

首次提交

2015年3月26日

首先提交符合 QC 标准的

2015年3月26日

首次发布 (估计的)

2015年3月27日

研究记录更新

最后更新发布 (实际的)

2026年10月29日

上次提交的符合 QC 标准的更新

2026年10月28日

最后验证

2026年3月31日

更多信息

与本研究相关的术语

其他研究编号

  • 150100
  • 15-DK-0100

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.